Pharmacology of mitochondrial potassium channels: dark side of the field  by Szewczyk, Adam et al.
FEBS Letters 584 (2010) 2063–2069journal homepage: www.FEBSLetters .orgReview
Pharmacology of mitochondrial potassium channels: dark side of the ﬁeld
Adam Szewczyk a,*, Anna Kajma a, Dominika Malinska a, Antoni Wrzosek a, Piotr Bednarczyk a,b,
Barbara Zabłocka c, Krzysztof Dołowy b
a Laboratory of Intracellular Ion Channels, Nencki Institute of Experimental Biology, 3 Pasteur St., 02-093 Warsaw, Poland
bDepartment of Biophysics, Warsaw University of Life Sciences SGGW, 159 Nowoursynowska St., 02-776 Warsaw, Poland
cMolecular Biology Unit, Mossakowski Medical Research Centre PAS, 5 Pawinskiego St., 02-106 Warsaw, Poland
a r t i c l e i n f o a b s t r a c tArticle history:
Received 12 January 2010
Revised 25 January 2010
Accepted 15 February 2010
Available online 20 February 2010





ATP0014-5793/$36.00  2010 Federation of European Bio
doi:10.1016/j.febslet.2010.02.048
Abbreviations: mitoBKCa channel, mitochondrial
vated potassium channel; BKCa channel, large-condu
sium channel; KATP channel, plasma membrane ATP-r
mitoKATP channel, mitochondrial ATP-regulated potas
urea receptor; 5-HD, 5-hydroxydecanoic acid; KCO,
SDH, succinate dehydrogenase
* Corresponding author. Fax: +48 22 8225342.
E-mail address: adam@nencki.gov.pl (A. SzewczykMitochondrial potassium channels play an important role in cytoprotection. Potassium channels in
the inner mitochondrial membrane are modulated by inhibitors and activators (potassium channel
openers) previously described for plasma membrane potassium channels. The majority of mito-
chondrial potassium channel modulators exhibit a broad spectrum of off-target effects. These
include uncoupling properties, inhibition of the respiratory chain and effects on cellular calcium
homeostasis. Therefore, the rational application of channel inhibitors or activators is crucial to
understanding the cellular consequences of mitochondrial channel inhibition or activation. More-
over, understanding their side-effects should facilitate the design of a speciﬁc mitochondrial chan-
nel opener with cytoprotective properties. In this review, we discuss the complex interactions of
potassium channel inhibitors and activators with cellular structures.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The pharmacology of mitochondrial potassium channels is
mainly based on drugs designed for plasma membrane potassium
channels [1–3]. Three types of potassium channels have been
reported to contribute to the potassium permeability of mitochon-
dria: the ATP-regulated potassium channel, the large-conductance
(and intermediate-conductance) Ca2+-activated potassium
channels and the voltage-gated Kv1.3 channel. The majority of
potassium channel inhibitors and activators interact both with
plasma membrane and mitochondrial ATP-regulated potassium
channels (mitoKATP channels) [4]. The only exception is thought
to be the ATP-regulated potassium channel (KATP channel) inhibitor
HMR1098 [5]. This drug blocks plasma membrane but not
mitochondrial ATP-regulated potassium channels. All other drugs
exhibit cross-reactivity between plasma and mitochondrial potas-
sium channels. For example, the K+ channel opener (KCO) NS1619
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potassium channels in the mitochondrial inner membrane. In some
tissues, certain drugs seem to target mitochondrial channels more
speciﬁcally than plasma membrane channels. Therefore, some sub-
stances, such as the potassium channel openers diazoxide and
BMS-191095 and the potassium channel inhibitor 5-hydroxydeca-
noic acid, are considered ‘‘mitochondrial potassium channel mod-
ulators” [6]. Our view is that this opinion must be considered
carefully, especially because these mitochondrial potassium chan-
nel modulators have various off-target effects, due, for example, to
their uncoupling properties or their interaction with respiratory
chain enzymes. The rational application of potassium channel
inhibitors and activators in mitochondrial studies is based on de-
tailed knowledge of their side-effects. In our opinion, the success-
ful usage of these drugs often depends on experimental assays or
multiple drug applications.
mitoKATP channels have been identiﬁed in the inner mitochon-
drial membranes of liver, brain, kidney, cardiac and skeletal muscle
cells [3,7–9]. Similar channels have been described in amoeba
mitochondria [10]. The mitochondrial large-conductance Ca2+-acti-
vated potassium channel (mitoBKCa channel) was originally identi-
ﬁed in mitochondria of human glioma cells [11]. Later, a similar
channel was observed in cardiac muscle, skeletal muscle and brain
mitochondria (for review see: [8]). Recently, we have shown the
presence of mitoBKCa channels in plant mitochondria [12]. The
margatoxin-sensitive Kv1.3 channel was identiﬁed in the innerlsevier B.V. All rights reserved.
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expression of the two-pore domain TASK-3 channels in keratino-
cytes and melanoma cells has been reported [14]. Patch-clamping
of mitoplasts isolated from human colon carcinoma cells has per-
mitted the identiﬁcation of the intermediate-conductance Ca2+-
activated K+-selective KCa 3.1 channel [15]. Recently, this channel
has been detected in other cell types [16].
The molecular identities of the mitochondrial potassium chan-
nels are unknown [17]. Several observations of the pharmacologi-
cal proﬁle and immunoreactivity with speciﬁc antibodies suggest
that the mitoKATP channel belongs to the inwardly rectifying K+
channel family Kir6.x. The use of speciﬁc antibodies has demon-
strated the existence of Kir6.1, Kir6.2 and sulfonylurea receptor
(SUR2A) subunits in ventricular myocyte mitochondria. Recently,
it was hypothesised that a complex of ﬁve proteins in the mito-
chondrial inner membrane is capable of transporting K+ with char-
acteristics similar to those of the mitoKATP channels. Similar to the
plasma membrane KATP channels, mitoKATP probably include a sul-
fonylurea receptor (mitoSUR) [18]. More information is known
about the molecular identity of mitoBKCa. The BKCa channel b4 sub-
unit is expressed in neuronal mitochondria, where it is preferen-
tially localised to the mitochondrial inner membrane [19]. These
ﬁndings, in addition to data showing the mitochondrial localisation
of the BKCa channel a subunit in neurons [20], suggest that b4 is
the auxiliary subunit of the neuronal mitoBKCa channel.
The primary function of mitochondrial potassium channels is to
permit K+ transport into the mitochondrial matrix [21]. This trans-
port can be observed as a macroscopic ﬂux [6,22,23] or at the sin-
gle-channel level with the use of patch-clamp [11,13,15,24] and
planar lipid bilayer techniques [23,25–28]. The inﬂux of K+ could
be involved inmitochondrial volume homeostasis, changes inmito-
chondrial membrane potential or pH gradient and respiration
[29–33]. Additionally, the inﬂux of K+ ions across the inner mito-
chondrial membrane modulates reactive oxygen species synthesis
[34]. The cytoprotective effect of potassium channel openers acting
onmitochondriawasobserved in cardiac andneuronal systems [35].
In this review, we describe the effects of mitochondrial potas-
sium channel modulators on different cellular targets (see Fig. 1):Fig. 1. Schematic representation of the interactions of potassium channel modulators wi
indicated as  and inhibition as €.it is our view of the state of mitochondrial potassium channels
pharmacology. The pharmacology of mitochondrial potassium
channels has been previously reviewed [3,7,35]. Intracellular tar-
gets of antidiabetic sulfonylureas and potassium channels have
also been described [36,37].
2. Potassium channel openers and inhibitors of mitochondrial
ATP-regulated potassium channels
Numerous openers of KATP channels, including pinacidil, nico-
randil and diazoxide, have been shown to protect tissue against
ischemia and reperfusion-induced damage [1,38]. The currently
prevailing view is that the protection results from activation of
the potassium channels in the inner mitochondrial membrane
[39,40]. After diazoxide had been shown to be more selective to-
wards mitochondrial than plasma membrane KATP channels, it be-
came the most widely applied opener in studies of KCO-mediated
cytoprotection [41]. Another valuable tool for studying the physio-
logical role of mitochondrial potassium channels is 5-hydroxy-
decanoic acid (5-HD), an inhibitor of mitoKATP channel. In
contrast to the antidiabetic sulfonylurea glibenclamide, another
popular KATP inhibitor that acts on both mitochondrial and plasma
membrane channels, 5-HD is considered selective for mitoKATP
channels [41]. However, all of the aforementioned drugs have
off-target effects, which should be kept in mind while interpreting
the experimental results.
Diazoxide and pinacidil were shown to uncouple mitochondrial
oxidative phosphorylation in a potassium-independent manner
[42]. The protonophoric properties of these drugs were demon-
strated by measurements of H+ currents in planar phospholipid
membranes and 3H ﬂux across chloroform layers. The same study
showed that the classical protonophore 2,4-dinitrophenol protects
the ischemic heart to a similar extent as diazoxide and pinacidil.
The concentrations of the potassium channel openers used in this
study (100 lM) were relatively high. As cytoprotective effects
can usually be achieved with lower doses of these drugs, such high
concentrations should be avoided in studies of the role of potas-
sium channels in preconditioning. Glibenclamide, which is knownth mitochondrial potassium channels and selected non-speciﬁc targets. Activation is
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uncouple mitochondria [37] and to activate mitochondrial mega-
channels [45].
Diazoxide can also interact with the F(1) complex of mitochon-
drial ATP synthase, facilitating the binding of IF(1), the endogenous
inhibitor of the ATP synthase, to the F(1) subunit [46]. Upon bind-
ing, IF(1) inhibits ATP synthase-mediated ATP hydrolysis in the
context of a low mitochondrial electrochemical gradient. This phe-
nomenon is partially responsible for ATP depletion during ische-
mia. Therefore, this activity of diazoxide could contribute to its
cytoprotective activity, leading to improved ATP preservation in
ischemic conditions.
Both diazoxide and pinacidil inhibit the activity of the mito-
chondrial respiratory chain in a potassium channel-independent
manner [47,48]. Interestingly, they appear to act on different respi-
ratory complexes, as diazoxide inhibits respiration supported by
the complex II substrate, succinate, while pinacidil decreases oxy-
gen consumption driven by the complex I substrates pyruvate and
malate. These effects are insensitive to the mitoKATP inhibitors gli-
benclamide and 5-HD, conﬁrming that they are not related to the
activation of potassium channels.
Inhibition of succinate dehydrogenase (SDH, respiratory com-
plex II) by diazoxide has also been demonstrated by other authors
[49–52]. Diazoxide interacts with cytochrome b560 at complex II,
close to the ubiquinone-binding site, which is probably the cause
of decreased succinate oxidation [52]. This off-target effect of the
K+ channel opener can contribute to the diazoxide-mediated stim-
ulation of mitochondrial reactive oxygen species generation, which
appears to be crucial for the preconditioning effect induced by the
opener [50,51]. Diazoxide-induced ROS generation is sensitive to
stigmatellin, an inhibitor of respiratory complex III, which shows
that diazoxide stimulates superoxide synthesis at the Qo site of
complex III [50]. The same site is responsible for ROS generation
stimulated by classical SDH inhibitors. In addition, SDH inhibitors,
like 3-nitropropionic acid, also induce preconditioning in experi-
mental ischemia and reperfusion [53]. This ﬁnding favours the
view that diazoxide-mediated inhibition of the respiratory chain
contributes to the cytoprotective action of the drug.
SDH inhibition is also responsible for the vasodilatory action of
diazoxide [54]. In general, the vasodilatory activity of potassium
channel openers results from the activation of potassium channels
located in the plasma membrane of smooth muscle cells, leading to
vessel relaxation. This mechanism explains pinacidil-induced vaso-
dilation, as the dilatory activity of this opener is not observed in
cells lacking SUR2, the regulatory subunit of the KATP channels
[54]. Surprisingly, knocking out SUR2 does not affect diazoxide-
induced vessel relaxation, which, in contrast, is abolished by
administration of the antioxidant MnTMPyP. MnTMPyP also inhib-
its the vasodilatory effect of the SDH inhibitor atpenin, which links
the vasodilatory action of diazoxide to the inhibition of SDH by this
drug rather than to the activation of KATP channels.
Some authors postulate that diazoxide does not activate the
mitoKATP channels directly, but rather by stimulating the transloca-
tion of PKCe to the mitochondria and promoting channel phos-
phorylation [55]. This hypothesis is based on observations
indicating that diazoxide-induced ﬂavoprotein oxidation, consid-
ered a hallmark of mitochondrial potassium channel activation, is
abolished by PKCe inhibitors. Possible phosphorylation events in-
volved in the regulation of mitoKATP channels by diazoxide were
also shown at the single-channel level [56].
5-HD is a mitoKATP inhibitor that is often applied to conﬁrm that
the effects observed in the presence of KCOs result from the
activation of mitoKATP channels. However, the speciﬁcity of this
channel modulator has also been questioned. Molecular modelling
demonstrates that both 5-HD and glibenclamide can interact with
mitochondrial ADP/ATP carriers [57]. Moreover, 5-HD can bemetabolised to its CoA derivative and then enter the b-oxidation
pathway [47], so it is not clear whether the channel inhibition
observed in vivo is mediated by 5-HD itself or by one of its metab-
olites. Therefore, the efﬁcacy of the inhibition may depend on cell
type and metabolic state. Moreover, Hanley et al. [47] postulate
that reversing the effects of diazoxide with 5-HD does not
necessarily result from the inhibition of mitoKATP channels. 5-HD
can bypass the diazoxide-mediated inhibition of succinate dehy-
drogenase by feeding the electrons to the ubiquinone pool via
ETF-dehydrogenase. In some of the studies, the reversal of the
effects of mitoKATP openers could be achieved only with quite high
(millimolar) concentrations of 5-HD [58,59]. Therefore, it is likely
that its anti-KCO effects are a consequence of metabolic effects
rather than of pharmacological modulation of channel activity.
Additionally, the guanidine-derived KATP inhibitor U-37883A stim-
ulates the synthesis of phosphatidylserine in the endoplasmic
reticulum [60].
Our view is that these examples suggest that the application of
diazoxide or 5-HD without any further conﬁrmation of mitoKATP
involvement may lead to misinterpretation of the observed
phenomena.3. BK channel openers and mitochondria
Large-conductance Ca2+-activated potassium channels (BKCa
channels) are ubiquitously distributed among tissues. BKCa chan-
nels can be activated by changes of membrane potential or intra-
cellular calcium ions separately or by both factors synergistically
[61]. In mammalian tissues, they are expressed in both excitable
and non-excitable cells, where they are involved in the regulation
of many physiological functions [62]. They are also present in in-
sects and nematodes. BKCa channels were discovered in mamma-
lian smooth muscle cells and then found in brain, bladder,
cochlea, pancreatic islets [63] and endothelial cells [64–66]. BKCa
channels are important in the nervous system [67], where they
act as regulators of neuronal excitability and neurotransmitter re-
lease [68]. Previous studies suggest that BKCa channel modulation
can also alter the ﬁring properties of neurons in central and periph-
eral nociceptive pathways [69]. Interestingly, putative BKCa chan-
nels have also been found in the mitochondrial inner membrane
of cardiomyocytes (mitoBKCa channel) [70], in the human glioma
cell line LN229 [11] and in brain mitochondria [19,71]. Large-con-
ductance Ca2+-activated potassium channels, which are located in
the inner mitochondrial membrane, have been implicated in cyto-
protection against ischemia and reperfusion injury in the isolated
perfused guinea pig heart [70,72]. Recent studies have suggested
that this cytoprotective effect is independent of the activation of
BKCa channels [73,74].
In the last decade, more attention has focused on a group of
modulators of BKCa channels. The available literature about the
activators and inhibitors of BKCa channels mainly concerns those
located in the plasma membrane [69,75]. Because proposed poten-
tial activators or inhibitors of the BKCa channels were originally de-
signed for those in the plasma membrane, caution is required
when using them for experiments on mitochondrial channels.
The best-studied class of mitochondrial BKCa channels openers
are benzimidazolones. These include NS1619, NS004, NS1604,
NS11021 and NS1643. They are small synthetic molecules, which
are the most often used pharmacological tools and models of the
novel heterogeneous synthetic openers [75]. When they interact
with the plasma membrane potassium channels, they cause cell
membrane hyperpolarisation. However, when they activate the
channels in the inner mitochondrial membrane, this membrane
is depolarised. Benzimidazolone NS1619 is the most frequently
used activator of the plasmalemmal and mitoBKCa channels.
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tered in micromolar concentrations, modulates the activity of the
calcium-gated chloride channels in smooth muscle cells isolated
from rabbit pulmonary arteries. Application of NS1619 increases
the probability of opening of the chloride channel [76]. Addition-
ally, Park and co-workers [77] have demonstrated a novel action
of the channel opener NS1619. They have shown that NS1619
inhibits the plasma membrane L-type calcium channels in ventric-
ular myocytes isolated from the rat. The inhibitory effect was not
reversible by iberiotoxin or paxilline (BKCa channel inhibitors). Pre-
treatment with inhibitors of protein kinases that regulate L-type
calcium channels did not block this effect of NS1619. The authors
suggested that NS1619 has a similar structure to mibefradil, an-
other inhibitor of L-type calcium channels [77].
The benzimidazolone analogues NS1619 and NS004 have been
proposed to be pharmacological tools for the treatment of cystic
ﬁbrosis. Using the whole-cell conﬁguration of the patch-clamp
technique, NS1619 and NS004 potentiated the macroscopic chlo-
ride current in mouse ﬁbroblast cells that stably expressed the mu-
tated CFTR channel [78]. NS004 also increased chloride efﬂux via
chloride channels in Vero cells [79]. Additionally, patch-clamp
cell-attached experiments indicate that benzimidazolone ana-
logues act in a similar manner to genistein, one of the proposed
therapeutic drug candidates for cystic ﬁbrosis [78]. Patel et al.
[80] suggest that NS1619 inhibits acetylcholine-evoked electrical
ﬁeld stimulation in smooth muscle cells from the guinea pig tra-
chea. This ﬁnding is unrelated to BKCa channel activation [80].
NS1619 was found to be a blocker of voltage-dependent calcium
channels [81,82] and of L-type calcium currents in the bovine tra-
chea and to prevent levcromakalim-induced activation of KATP
channels in smooth muscle cells from rat vein and the delayed-rec-
tiﬁer current [83].
Some data indicate that mitochondrial potassium channel open-
ers have non-speciﬁc effects changing mitochondrial bioenergetic
functions. In a glioma cell line, it has been shown that 20 lM
NS1619 and NS004 inhibit mitochondrial respiration in the pres-
ence of uncoupling substances. This effect is due to the interactions
of NS1619 and NS004 with complex I of the mitochondrial respira-
tory chain [84]. A similar inhibition of mitochondrial respiration
has been shown in isolated cardiacmitochondria [85]. In mitochon-
dria isolated from rat hearts, NS1619 reduces the state 3 respiratory
rate in the presence of substrates for complex I and complex II in
potassium-rich or in potassium-free media. These results suggest
the presence of another target for NS1619 in the electron transport
chain. In the same media, NS1619 depolarises mitochondria. Mea-
surements of mitochondrial volume by the light-scattering method
reveal that NS1619 promotes swelling independent of an effect on
mitochondrial BKCa channels [86]. Additionally, the same effect is
observed in mitochondria isolated from liver. After treatment with
NS1619, a decrease in light-scattering (increased mitochondrial
volume) in potassium-containing and in potassium-free media is
observed. This ﬁnding suggests an effect of NS1619 that is unrelated
to its effects on BKCa channels [87].
The ﬁrst data concerning the cytoprotective effect of mitochon-
drial BKCa channel activation by NS1619 were reported in 2002, in
guinea pig hearts incubated with NS1619 before ischemic insult.
The effect of NS1619 was antagonised by paxilline, showing that
it is linked to the BKCa potassium channel [88]. Similar effects have
been demonstrated in neuronal tissue. In cortical neuronal cells
treated with increasing doses of NS1619 for 3 days before being
stimulation with a toxic agent, NS1619 caused delayed neuronal
preconditioning. Surprisingly, protection against hydrogen perox-
ide was not reversed by channel inhibitors, but rather by the super-
oxide dismutase mimetic M404 001 and by the PI3K inhibitor
wortmannin. The authors suggested that the neuroprotective ac-
tion of NS1619 is the result of the mitochondrial electron transportchain inhibition, the generation of reactive oxygen species, and the
activation of PI3K-dependent signalling. In isolated neuronal mito-
chondria [88] and intact neurons [74], NS1619 induces mitochon-
drial depolarisation and the generation of ROS. BKCa channel
inhibitors do not abolish this effect. Additionally, NS1619 increases
the phosphorylation of Akt and GSK3 and induces BK channel-inde-
pendent mitochondrial depolarisation and ATP depletion after glu-
tamate excitotoxicty and oxygen-glucose deprivation. Prolonged
treatment of neurons with NS1619mildly reduces hydrogen perox-
ide–dependent activation of caspases 3 and 7 [88]. NS1619 induces
immediate neuronal preconditioning against glutamate excitotox-
icty, independent of BKCa channel activation. Application of
NS1619 decreases the levels of intracellular calcium and reactive
oxygen species after glutamate exposure [74].
In our opinion, caution must be exerted when using BKCa
channel inhibitors or activators targeting mitochondrial function.
Additionally, paxilline can inhibit calcium-dependent ATPases
when is applied at concentrations of 5–50 lM [89]. In rat cerebral
microsomes, paxilline inhibits 1,4,5-triphosphate (InsP3)-depen-
dent calcium release [90].4. BK channel openers and calcium homeostasis
Indole carboxylate compounds such as ethyl-1-[[(4-chloro-
phenyl)amino]oxo]-2-hydroxy-6-triﬂuoromethyl-1H-indole-3-
carboxylate (CGS7184) have also been identiﬁed as BKCa channel
openers [91]. The mechanism of BKCa-opening by CGS7184 has
been studied in vascular smooth muscle cells by investigating
whole-cell BKCa current and single-channel activity using the
patch-clamp method [91]. The endothelium is another target of
BKCa channel openers [92]. Recently, it has been demonstrated that
the BK channel opener CGS7184 increases the biosynthesis of NO
in an endothelial cell line, causes the vasodilatation of the rat aortic
ring and increases coronary ﬂow in the isolated guinea pig heart
[92]. This channel opener raises the cytosolic Ca2+ concentration
and acts on the endothelium by activating NO synthase pathways
and modulating mitochondrial function, which could be triggered
by the CGS7184-induced modulation of intracellular Ca2+ homeo-
stasis in endothelial cells. Micromolar concentrations of CGS7184
double the amount of NO produced relative to control conditions.
The sources of the increase in Ca2+ concentration induced by
CGS7184 could be either intracellular stores or inﬂux from the
extracellular space. Calcium transients in the absence of extracel-
lular Ca2+ after treatment with CGS7184 have been observed. This
ﬁnding suggests involvement of intracellular stores in the increase
of Ca2+ caused by CGS7184. In addition, CGS7184 induces depolar-
isation of the mitochondria (and increase in respiration) in endo-
thelial cells. Similar effects were observed with the same channel
openers in human glioma cells [93].
Recently, it has been shown that other BKCa potassium channel
openers, NS1619 and NS11021, may alter the cellular calcium
homeostasis and that the action of these compounds may be re-
lated to the increased level of intracellular Ca2+, leading to modu-
lation of mitochondrial function [94]. The channel opener
NS11021 directly interacts with mitochondria causing speciﬁc K+
ﬂux [95].5. Pore-blocking peptides—hope for the future?
As described above, the majority of mitochondrial potassium
channel modulators exhibit broad off-target effects. Therefore,
using them to modulate mitochondrial potassium channels
in vivo is complicated.
Pore-blocking peptides are known to block diverse types of K+
channels with high afﬁnity. Therefore, they are useful tools in the
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architecture of the pore region of this class of channels. Most phar-
macological and structural characteristics of plasma membrane
potassium channels have been elucidated by applying high-afﬁnity
channel blockers isolated from scorpion venom [96]. They are the
most useful tools for studying potassium channel physiology.
Pore-blocking peptides such as iberiotoxin and charybdotoxin
may interact with mitoBKCa channels in cardiac muscle, skeletal
muscle and brain mitochondria (for review see [8]). Margatoxin
interacts with the mitochondrial Kv1.3 channel [13]. In our opin-
ion, the application of peptides (toxins) to study mitochondrial
potassium channels may open up new research opportunities.
The afﬁnity of peptide channel blockers is very sensitive to point
mutations both on blocker peptide and on channel protein. Thus,
there is a chance to synthesize mutated peptides blockers directed
speciﬁcally towards mitochondrial channels. Such mitochondria
speciﬁc channel blockers (or activators) might give an insight into
understanding of functional role of the channels in isolated mito-
chondria and physiological mechanisms of ischemic precondition-
ing as well as counting the channel density in inner mitochondrial
membranes in various cell types. Additionally, peptides may be
important in strategies for the discovery of new, speciﬁc modula-
tors of K+ channels [97].6. Conclusion
Mitochondria are a unique target for pharmacological interven-
tion due to their high membrane potential and alkaline matrix pH.
Consequently, mitochondria play the role of ‘‘antenna” for posi-
tively charged and lipophilic drugs or weak acids. Additionally,
the vigorous metabolic activity of mitochondria may be blocked
by potassium channel modulators. Despite extensive research on
mitochondrial potassium channels, a central question remains:
how does the opening of the potassium channels in the inner mito-
chondrial membrane protect cells against injury? Some explana-
tions are based on experiments involving the potassium channel
activators and inhibitors. As described above, interpretation of
the majority of experiments that use isolated mitochondria or cel-
lular/tissue systems must be done carefully.
Rational pharmacology of mitochondrial potassium channels is
based on molecular identiﬁcation of these channels. Moreover, it is
not clear why similar to plasma membrane potassium channels are
present in inner mitochondrial membrane. Is it a random process?
Concerning BKCa channel, both plasma membrane and mitochon-
drial protein are probably splice variants of the same gene product.
The pore-forming a-subunits of BKCa channels are encoded by a
single gene, KCNMA1, which undergoes extensive alternative
pre-mRNA splicing. Distinct splice variants mRNAs of a-subunits
may be expressed in the same cells and these properties could be
modiﬁed by oxidative stress. This hypothesis is indirectly con-
ﬁrmed by identiﬁcation of BKCa channel associated proteins pres-
ent in mitochondria [98]. Recent observations on viral potassium
channels suggest new mechanism on targeting similar membrane
proteins to plasma membrane and to inner membrane of mito-
chondria [99].
In summary, more speciﬁc modulators of these channels are re-
quired to understand their functional roles in mitochondria.Acknowledgements
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